Form 4: Dianthus Therapeutics Executive Edward Carr Awarded Stock Options
SEC Form 4 Filing
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, Inc., was granted stock options for 60,000 shares on February 3, 2025.
Summary
- On February 3, 2025, Edward Carr, the Chief Accounting Officer of Dianthus Therapeutics, Inc., was granted stock options.
- These options allow him to purchase 60,000 shares of Dianthus Therapeutics common stock at an exercise price of $22.07 per share.
- The options vest in equal monthly installments over four years, starting January 1, 2025, contingent upon Carr's continued service to the company.
- The options expire on February 2, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns executive interests with shareholder value.
Positives
- The granting of stock options to a key executive like the Chief Accounting Officer can be seen as a positive incentive for continued service and alignment with the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with those of the shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
- The size of the grant (60,000 shares) and the vesting schedule (monthly over four years) are typical for executive-level positions.
- Comparable companies in the biotech industry, such as Amgen, Gilead Sciences, and Biogen, routinely use stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Accounting Officer to contribute to the company's success.
- Employees may see this as a sign of the company's commitment to rewarding its key personnel.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Start date for monthly vesting of stock options. |
| February 3, 2025 | Date of the transaction (grant of stock options). |
| February 4, 2025 | Date of signature on the Form 4 filing. |
| February 2, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.